24916544|t|Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.
24916544|a|Alzheimer's disease (AD) is a neurodegenerative process involving amyloid-beta (Abeta) peptide deposition, neuroinflammation, and progressive memory loss. Here, we evaluated whether oral administration of retinoic acid receptor (RAR)alpha,beta agonist Am80 (tamibarotene) or specific retinoid X receptor (RXR) pan agonist HX630 or their combination could improve deficits in an AD model, 8.5-month-old amyloid-beta protein precursor 23 (AbetaPP23) mice. Co-administration of Am80 (0.5 mg/kg) and HX630 (5 mg/kg) for 17 days significantly improved memory deficits (Morris water maze) in AbetaPP23 mice, whereas administration of either agent alone produced no effect. Only co-administration significantly reduced the level of insoluble Abeta peptide in the brain. These results thus indicate that effective memory improvement via reduction of insoluble Abeta peptide in 8.5-month-old AbetaPP23 mice requires co-activation of RARalpha,beta and RXRs. RARalpha-positive microglia accumulated Abeta plaques in the AbetaPP23 mice. Rat primary microglia co-treated with Am80/HX630 showed increased degradation activity towards 125I-labeled oligomeric Abeta1-42 peptide in an insulin-degrading enzyme (IDE)-dependent manner. The co-administration increased mRNA for IDE and membrane-associated IDE protein in vivo, suggesting that IDE contributes to Abeta clearance in Am80/HX630-treated AbetaPP23 mice. Am80/HX630 also increased IL-4Ralpha expression in microglial MG5 cells. The improvement in memory of Am80/HX630-treated AbetaPP23 mice was correlated with the levels and signaling of hippocampal interleukin-4 (IL-4). Therefore, Am80/HX630 may promote differentiation of IL-4-responsive M2-like microglia and increase their activity for clearance of oligomeric Abeta peptides by restoring impaired IL-4 signaling in AbetaPP23 mice. Combination treatment with RAR and RXR agonists may be an effective approach for AD therapy. 
24916544	95	100	mouse	Species	10090
24916544	110	129	Alzheimer's disease	Disease	MESH:D000544
24916544	131	150	Alzheimer's disease	Disease	MESH:D000544
24916544	152	154	AD	Disease	MESH:D000544
24916544	211	216	Abeta	Gene	11820
24916544	238	255	neuroinflammation	Disease	MESH:D000090862
24916544	273	284	memory loss	Disease	MESH:D008569
24916544	336	374	retinoic acid receptor (RAR)alpha,beta	Gene	19401;218772
24916544	383	387	Am80	Chemical	MESH:C061133
24916544	389	401	tamibarotene	Chemical	MESH:C061133
24916544	453	458	HX630	Chemical	MESH:C422175
24916544	509	511	AD	Disease	MESH:D000544
24916544	579	583	mice	Species	10090
24916544	606	610	Am80	Chemical	MESH:C061133
24916544	627	632	HX630	Chemical	MESH:C422175
24916544	678	693	memory deficits	Disease	MESH:D008569
24916544	727	731	mice	Species	10090
24916544	1024	1028	mice	Species	10090
24916544	1055	1068	RARalpha,beta	Gene	19401;218772
24916544	1079	1087	RARalpha	Gene	24705
24916544	1119	1124	Abeta	Gene	11820
24916544	1150	1154	mice	Species	10090
24916544	1156	1159	Rat	Species	10116
24916544	1194	1198	Am80	Chemical	MESH:C061133
24916544	1199	1204	HX630	Chemical	MESH:C422175
24916544	1251	1255	125I	Chemical	MESH:C000614960
24916544	1299	1323	insulin-degrading enzyme	Gene	25700
24916544	1325	1328	IDE	Gene	25700
24916544	1389	1392	IDE	Gene	25700
24916544	1417	1420	IDE	Gene	25700
24916544	1454	1457	IDE	Gene	25700
24916544	1473	1478	Abeta	Gene	11820
24916544	1492	1496	Am80	Chemical	MESH:C061133
24916544	1497	1502	HX630	Chemical	MESH:C422175
24916544	1521	1525	mice	Species	10090
24916544	1527	1531	Am80	Chemical	MESH:C061133
24916544	1532	1537	HX630	Chemical	MESH:C422175
24916544	1553	1563	IL-4Ralpha	Gene	16190
24916544	1589	1592	MG5	CellLine	CVCL:5556
24916544	1629	1633	Am80	Chemical	MESH:C061133
24916544	1634	1639	HX630	Chemical	MESH:C422175
24916544	1648	1657	AbetaPP23	CellLine	CVCL:B2RV
24916544	1658	1662	mice	Species	10090
24916544	1723	1736	interleukin-4	Gene	16189
24916544	1738	1742	IL-4	Gene	16189
24916544	1756	1760	Am80	Chemical	MESH:C061133
24916544	1761	1766	HX630	Chemical	MESH:C422175
24916544	1798	1802	IL-4	Gene	16189
24916544	1888	1893	Abeta	Gene	11820
24916544	1925	1929	IL-4	Gene	16189
24916544	1943	1952	AbetaPP23	CellLine	CVCL:B2RV
24916544	1953	1957	mice	Species	10090
24916544	2040	2042	AD	Disease	MESH:D000544
24916544	Negative_Correlation	MESH:C061133	MESH:D000544
24916544	Negative_Correlation	MESH:C000614960	MESH:C422175
24916544	Positive_Correlation	MESH:C061133	19401
24916544	Positive_Correlation	MESH:C422175	16189
24916544	Positive_Correlation	MESH:C061133	16190
24916544	Negative_Correlation	MESH:C000614960	MESH:C061133
24916544	Positive_Correlation	MESH:C422175	16190
24916544	Positive_Correlation	MESH:C061133	218772
24916544	Negative_Correlation	MESH:C061133	11820
24916544	Negative_Correlation	MESH:C422175	11820
24916544	Negative_Correlation	MESH:C061133	MESH:D008569
24916544	Positive_Correlation	MESH:C061133	16189
24916544	Association	11820	25700
24916544	Association	MESH:C061133	25700
24916544	Negative_Correlation	MESH:C422175	MESH:D008569
24916544	Positive_Correlation	MESH:C422175	25700
24916544	Association	11820	24705
24916544	Cotreatment	MESH:C061133	MESH:C422175
24916544	Association	MESH:D000544	11820
24916544	Association	MESH:D008569	11820
24916544	Negative_Correlation	MESH:C422175	MESH:D000544

